Novavax slashes sales guidance in half, stock plunges 34%

In an unsigned statement issued separately from money final results, Novavax executives reported that the adjustment was made “to account for a number of evolving sector dynamics.”

“We continue being self-confident in our vaccine as a sturdy added option,” executives stated. “Its aggressive product profile contains our vaccine’s efficacy, effectively-tolerated safety profile, toughness of safety and skill to handle each latest and long run variant strains.”

“In Q3, we are presently generating remarkable progress,” the assertion continued. “We have shipped over 23 million doses due to the fact the commencing of July and, while in some instances shipping timing could be pushed into 2023, we do not expect whole contracted need to adjust below the bulk of our Advance Obtain Agreements.”

For the second quarter, Novavax reported a loss of $510.5 million, or $6.53 a share, down from a loss of $4.75 a share a year in the past, on revenue of $185.9 million, down from $298 million previous calendar year. Analysts on regular expected earnings of $5.54 a share on gross sales of $1.02 billion, according to FactSet.

Shares shut with a 5% drop at $57.25, then dove about 34% in soon after-hours trading. The stock has currently declined 60% so considerably this 12 months, as the S&P 500 index
SPX,
-.12%
has dropped 13%.